Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.30 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.30 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550660 | 0.90 | TNF (0.38) | TNFHDAC3HDAC1HDAC6TIPARP | |
| SCHEMBL25320186 | 0.81 | TNF (0.36) | TNFHDAC3HDAC1HDAC6JAK2 | |
| SCHEMBL25318628 | 0.81 | TNF (0.41) | TNFHDAC3HDAC1HDAC6PSMB5 | |
| SCHEMBL30550681 | 0.77 | PRMT5 (0.34) | TNFHDAC3HDAC1HDAC6 | |
| SCHEMBL25898854 | 0.77 | PRMT5 (0.34) | TNFHDAC3HDAC1HDAC6 | |
| SCHEMBL25321355 | 0.75 | TIPARP (0.32) | TNFHDAC3HDAC1HDAC6TIPARP | |
| SCHEMBL30550612 | 0.75 | TIPARP (0.32) | TNFHDAC3HDAC1HDAC6TIPARP | |
| SCHEMBL25321350 | 0.75 | TIPARP (0.32) | TNFHDAC3HDAC1HDAC6TIPARP | |
| SCHEMBL25898500 | 0.74 | TIPARP (0.34) | TNFHDAC3HDAC1HDAC6JAK2 | |
| SCHEMBL25321504 | 0.71 | TNF (0.34) | TNFHDAC3HDAC1HDAC6TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TNF 4831/4885HDAC3 83/4885HDAC1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.